Disease · MONDO_0005060

liposarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. liposarcoma. Diseases, record MONDO_0005060. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005060

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: liposarcoma; Open Targets
Open Targets ID: MONDO_0005060; Open Targets
Other names: lip sarcoma, liposarcoma, malignant, sarcoma of lip; Open Targets
Disease Ontology: DOID:3382; Disease Ontology
MeSH: D008080; MeSH
NCI Thesaurus: C3194; NCI Thesaurus
Orphanet: ORPHA:69078; Orphanet
Highest stage of its drugs: Approval, for 2 of its 45 drugs, from DailyMed and EMA Human Drugs; Open Targets

Drugs45

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TRABECTEDIN	CHEMBL450449	Small molecule	Approval	DailyMed	11	10	10	Drugs and targets
ERIBULIN	CHEMBL1683590	Small molecule	Approval	EMA Human Drugs	7	4	4	Drugs and targets
PAZOPANIB	CHEMBL477772	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DACARBAZINE	CHEMBL476	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MILADEMETAN	CHEMBL4292264	Small molecule	Phase 3	TTD	2	1	1	Drugs and targets
ABEMACICLIB	CHEMBL3301610	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
ERIBULIN MESYLATE	CHEMBL1683544	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SELINEXOR	CHEMBL3545185	Small molecule	Phase 3	TTD	1	0	0	Drugs and targets
PALBOCICLIB	CHEMBL189963	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 45

See all 45 drugs

Targets81

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KIT	Mast/stem cell growth factor receptor Kit	6	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	6	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5156	Drugs and targets
TUBA1A	Tubulin	4	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	4	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets

1 to 10 of 81

See all 81 targets

Trials43

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01343277	A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma	Phase 3	579	2016-01-28	Advanced Liposarcoma or Leiomyosarcoma	DACARBAZINE, TRABECTEDIN	Its record names the disease	ClinicalTrials.gov
NCT01327885	Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma	Phase 3	452	2017-02-28	Soft Tissue Sarcoma	DACARBAZINE, ERIBULIN MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT00060944	A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer	Phase 2	271	2014-09-08	Liposarcoma, Leiomyosarcoma	TRABECTEDIN	Its record names the disease	ClinicalTrials.gov
NCT02357810	Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas	Phase 2	178	2020-08-10	Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Liposarcoma, Recurrent Osteosarcoma, Stage IV Adult Soft Tissue Sarcoma	PAZOPANIB HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01877382	A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas	Phase 1	107	2024-07-18	Advanced Solid Tumor, Lymphoma	MILADEMETAN	Its record names the disease	ClinicalTrials.gov
NCT01209598	PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma	Phase 2	90	2017-11-06	Sarcoma, Liposarcoma	PALBOCICLIB	Its record names the disease	ClinicalTrials.gov
NCT01653028	Alisertib in Treating Patients With Advanced or Metastatic Sarcoma	Phase 2	72	2016-12-28	Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Leiomyosarcoma, Recurrent Liposarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7	ALISERTIB	Its record names the disease	ClinicalTrials.gov
NCT02815995	Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes	Phase 2	57	2025-06-12	Advanced and/or Metastatic Sarcoma	DURVALUMAB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT03899805	A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas	Phase 2	57	2025-08-28	Sarcoma, Liposarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma	ERIBULIN, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01692496	Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial	Phase 2	52	2020-07-23	Advanced and / or Metastatic Liposarcoma	PAZOPANIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 43

See all 43 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Trabectedin vs Dacarbazine: serious adverse events	155 of 378	52 of 172	550	NCT01343277	Trial comparisons
Arm A: Eribulin Mesylate vs Arm B: Dacarbazine: deaths from any cause	198 of 228	206 of 224	452	NCT01327885	Trial comparisons
Arm A: Eribulin Mesylate vs Arm B: Dacarbazine: serious adverse events	76 of 228	71 of 224	452	NCT01327885	Trial comparisons
Trabectedin 1.5 mg/m2 vs Trabectedin 0.58 mg/m2: serious adverse events	48 of 130	41 of 130	260	NCT00060944	Trial comparisons
Palbociclib 200mg vs Palbociclib 125mg: serious adverse events	24 of 30	55 of 60	90	NCT01209598	Trial comparisons

Papers from its trials29

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36669146	RESULT	1	PubMed
19451433	RESULT	1	PubMed
10097144	RESULT	1	PubMed
42082272	DERIVED	1	PubMed
41325133	DERIVED	1	PubMed
38236580	DERIVED	1	PubMed
37767191	DERIVED	1	PubMed
35934010	DERIVED	1	PubMed
33960681	DERIVED	1	PubMed
32827353	DERIVED	1	PubMed

1 to 10 of 29

See all 29 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005060

GET https://conductscience.org/api/diseases/v1/MONDO_0005060/drugs?page=2

API reference For AI assistants